Search clinical trials for: Sodium Zirconium Cyclosilicate (SZC)

Total 67 results

AstraZeneca

Recruiting

Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study (CONTINUITY)

Chronic Kidney Disease | Hyperkalaemia

Spain, United Kingdom, Belgium, Italy, Netherlands, France, Germany
AstraZeneca

Recruiting

An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PEDZ-K)

Hyperkalaemia

China, Germany, United States, Ukraine, Spain, Japan, United Kingdom, Canada, Poland, Romania, Russian Federation, Brazil
AstraZeneca

Terminated

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Hyperkalemia

United States, Italy, Spain, Taiwan, Thailand, Vietnam, Russian Federation, Canada, Hungary, Mexico, China, Austria, Turkey, Brazil, Germany, Poland, Czechia, United Kingdom, Bulgaria, Slovakia, Peru, Ukraine, Japan, Argentina, Malaysia, ...
AstraZeneca

Completed

Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects (DIALIZE China)

Hyperkalemia

China
AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. (HARMONIZE Asia)

Hyperkalemia

China
AstraZeneca

Completed

A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia (HARMONIZE GL)

Hyperkalemia

Korea, Republic of, Taiwan, Russian Federation, Japan
AstraZeneca

Completed

ZS Ph2/3 Dose-response Study in Japan

Hyperkalemia

Japan
Barts & The London NHS Trust

Terminated

The ORTIZ Study: Optimising RASi Therapy With SZC (ORTIZ)

Diabetes Mellitus, Type 2 | CKD | Hyperkalemia

United Kingdom
AstraZeneca

Recruiting

A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece (SHIELD)

Hyperkalaemia

Greece
Guangdong Provincial People's Hospital

Completed

Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy (SZC)

Hyperparathyroidism, Secondary | Hyperkalemia | Sodium Zirconium Cyclosilicate
ZS Pharma, Inc.

Completed

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
AstraZeneca

Completed

A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)

Hyperkalemia

Hong Kong
Leiden University Medical Center
AstraZeneca

Not yet recruiting

Sodium Zirconium Cyclosilicate to Allow Liberal Fruit and Vegetable Intake for Patients With CKD Stage 3b and 4 (LIBRAL)

Diet Modification | Chronic Kidney Disease | Hyperkalemia | Sodium Zirconium Cyclosilicate
ZS Pharma, Inc.

Completed

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

Hyperkalemia

United States, Germany, Australia, Netherlands, South Africa, Romania, United Kingdom
Brigham and Women's Hospital

Unknown

Potassium Binder in CKD Patients (With Hyperkalemia) (DiPo Trial)

Chronic Kidney Diseases | Hyperkalemia

United States
AstraZeneca

Completed

A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. (DIALIZE)

Hyperkalemia

United States, United Kingdom, Russian Federation, Japan
AstraZeneca

Terminated

Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease (NEUTRALIZE)

Chronic Kidney Disease | Metabolic Acidosis | Hyperkalaemia

United States, Puerto Rico
Karolinska Institutet
AstraZeneca

Completed

Healthy Diet Rich in Potassium to Chronic Kidney Disease With Sodium Zirconium Cyclosilicate: A Feasibility Study (HELPFUL)

Chronic Kidney Disease Stage 5 | Hyperkalemia | Chronic Kidney Disease stage4

Sweden
AstraZeneca

Terminated

Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure (PRIORITIZE HF)

Heart Failure

United States, Canada, Brazil, Slovakia, Hungary, Romania, Poland, Russian Federation, Bulgaria
ZS Pharma, Inc.

Completed

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

Hyperkalemia

United States, South Africa, Australia
Alexandria University

Recruiting

SZC Versus SPS for Treatment of Hyperkalemia in Hemodialysis Patients

Hyperkalemia

Egypt
AstraZeneca

Completed

Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia

Hyperkalemia

Japan
AstraZeneca

Terminated

Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia (GRAZE)

Hyperkalaemia

United States
Michael Fu
Göteborg University; AstraZeneca

Recruiting

OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failure (OPRA-HF)

Heart Failure | Hyperkalemia

Sweden
AstraZeneca

Completed

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8 (ENERGIZE)

Hyperkalemia

United States, Russian Federation, Italy, Denmark
AstraZeneca

Active, not recruiting

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone (REALIZE-K)

Heart Failure With Reduced Ejection Fraction | Hyperkalaemia

United States, Spain, Canada, Brazil, Hungary, Czechia, Ukraine, Poland, United Kingdom
Peking University First Hospital

Recruiting

The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)

Cardiac Arrhythmia | Potassium Imbalance | Dialysis; Complications

China
AstraZeneca

Terminated

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia (STABILIZE-CKD)

Renal Insufficiency, Chronic | Hyperkalemia

United States, Italy, Spain, Thailand, Vietnam, Turkey, Canada, Philippines, China, Malaysia, Taiwan, Brazil, Japan, Bulgaria, Russian Federation, Poland, Argentina, Mexico, Ukraine, India, Puerto Rico
University of California, Irvine

Recruiting

Comparison of Potassium Binders in the ER (KBindER)

Acute Hyperkalemia | Oral Potassium Binders

United States
AstraZeneca
Parexel

Completed

Study to Assess the Effect of Sodium Zirconium Cyclosilicate on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects

Hyperkalaemia

Germany
Pharma VAM

Unknown

Clinical Study in the Treatment of Patients With COVID-19

COVID-19

Russian Federation
Diffusion Pharmaceuticals Inc

Terminated

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects (INTACT)

Glioblastoma

United States
TScan Therapeutics, Inc.

Recruiting

A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation

Myelodysplastic Syndromes | AML | ALL, Adult

United States
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes (MANATEE-T1D)

Cardiovascular Diseases | Type 1 Diabetes | Diabetic Kidney Disease | Endothelial Dysfunction | Insulin Sensitivity

United States
Tunis University

Completed

0.9% Saline Versus Balanced Solutions in Severe Diabetic Ketoacidosis

Metabolic Ketoacidosis | Ketoacidemia | Acetonemia | Acetonuria

Tunisia
Virginia Commonwealth University
American Heart Association

Completed

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

Heart Failure

United States
Ciusss de L'Est de l'Île de Montréal
Medasense Biometrics Ltd

Completed

Impact of Nociceptive-Level (NOL) Intraoperative Guided Analgesia During Gynecological Laparoscopic Surgery Under General Anesthesia (NOLGYN)

Hysterectomy | Gynecologic Laparoscopic Surgery | Oophorectomy

Canada
International Vaccine Institute
Inovio Pharmaceuticals; Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19

Coronavirus Infection | SARS-CoV 2

Korea, Republic of
AbbVie
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Psoriasis

United States, Germany, United Kingdom
Baxter Healthcare Corporation
Halozyme Therapeutics

Completed

Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration (INFUSE-Cftrx)

Healthy
University Hospital, Rouen

Not yet recruiting

Screening for Subclinical Antibody Mediated Rejection and Efficacy of Belatacept in the Context of de Novo Donor Specific Antibody After Kidney Transplantation (BELA-M-R) (BELA-M-R)

Kidney Transplant Rejection
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

HIV Infections

United States
International AIDS Vaccine Initiative
Beth Israel Deaconess Medical Center, Boston MA; Ragon Institute of MGH, MIT... and other collaborators

Completed

Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults

HIV Infection

United States
Neopharma Japan Co., Ltd.
Parexel

Withdrawn

A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria

Malaria
Indiana University
Agency for Healthcare Research and Quality (AHRQ)

Completed

Short Stay Unit vs Hospitalization in Acute Heart Failure (SSU-AHF)

Acute Heart Failure

United States
PhaseBio Pharmaceuticals Inc.

Completed

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

Type 2 Diabetes Mellitus

United States
Mayo Clinic
Patient-Centered Outcomes Research Institute

Active, not recruiting

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Type 2 Diabetes | Cardiac Disease

United States
University Hospital, Basel, Switzerland

Active, not recruiting

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (Hypo-PrEA)

Postprandial Hypoglycemia

Switzerland
Columbia University

Completed

Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 (IMPROVE)

COVID-19 | Venous Thromboses | Arterial Thrombosis

United States
Retina Clinic, Sao Paulo, Brazil

Completed

Comparison of Three Different Anesthetic Approaches for Intravitreal Injections

Pain

Brazil

3

Subscribe